TLT-101

TLT-101 is a first-in-class gene therapy developed to address the root cause of failing heart muscle in conditions such as non-ischemic dilated cardiomyopathy (DCM) and chronic heart failure. It employs a recombinant adeno-associated virus (AAV) vector to deliver the human BIN1 cardiac isoform gene directly to cardiomyocytes. The therapeutic mechanism centers on restoring or enhancing BIN1 protein function, which is critical for maintaining t-tubule architecture and proper calcium handling in heart muscle cells. Loss of cBIN1 leads to disorganization of these structures, contributing to impaired contraction and relaxation seen in heart failure. By restoring cBIN1 levels, TLT-101 aims to reverse remodeling, improve cardiac function, and potentially provide durable recovery from advanced forms of heart failure. Extensive preclinical studies have demonstrated robust efficacy and safety across multiple animal models[1][2][3][4][5][7].

Other names

TLT 101TLT101TLT-101cBIN1 gene therapycBIN-1 gene therapycBIN 1 gene therapy